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What is known? 26 
x Cervical cancer disproportionately affects women from high deprivation backgrounds  27 
x Uptake of the HPV vaccine in the catch-up programme was lower and not equitable 28 
compared to the routine programme in Scotland  29 
x The HPV vaccine has previously been shown to be associated with significant 30 
reductions in HPV prevalence and cervical abnormalities in Scotland   31 
What this study adds? 32 
x We show a continued significant reduction in all grades of cervical intraepithelial 33 
neoplasia in vaccinated women with vaccine effect against CIN 3 greater in those 34 
from high deprivation backgrounds. 35 
x The HPV vaccine has reduced health inequalities in cervical cancer despite 36 
inequitable uptake in the catch-up programme.    37 
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ABSTRACT 52 
Background Cervical cancer disproportionately affects women from lower socio-economic 53 
backgrounds. A human papillomavirus (HPV) vaccination programme was introduced in 54 
Scotland in 2008 with uptake being lower and inequitable in a catch-up cohort run for the 55 
first three years of the programme compare to the routine programme. The socio-economic 56 
differences in vaccine uptake have the potential to further increase the inequality gap in 57 
regards to cervical disease. 58 
Methods Vaccination status was linked to demographical, cytological and colposcopic data, 59 
which is routinely collected by the Scottish HPV surveillance system. Incidence rates and 60 
relative risk of cervical intraepithelial neoplasia (CIN) 1, 2 and 3 in unvaccinated and 61 
vaccinated women were stratified by birth year and deprivation status using Poisson 62 
regression.   63 
Results Women who received three doses of HPV vaccine have significantly decreased risk 64 
of CIN 1, 2 and 3. Vaccine effectiveness was greater in those women from the most deprived 65 
backgrounds against CIN 2 and 3 lesions. Compared to the most deprived, unvaccinated 66 
women, the relative risk of CIN3 in fully vaccinated women in the same deprivation group 67 
was 0.29 (95% CI 0.2-0.43) compared to 0.62 (95% CI 0.4-0.97) in vaccinated women in the 68 
least deprived group.  69 
Conclusions The HPV vaccine is associated with significant reductions in both low- and 70 
high-grade CIN for all deprivation categories. However, the effect on high-grade disease was 71 
most profound in the most deprived women. These data are welcoming and allays the 72 
concern that inequalities in cervical cancer may persist or increase following the introduction 73 
of the vaccine in Scotland.  74 
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INTRODUCTION 81 
Cervical cancer is the most common cancer in women under the age of 35 in the UK with 82 
persistent high-risk (HR) human papillomavirus infection being the principle risk factor.[1, 2] 83 
HPV immunisation has been offered to all 12 to 13 year old girls in Scotland since September 84 
2008 with uptake of all three doses of vaccine exceeding 90% each year within this routine 85 
cohort.[3] In addition, a catch-up programme was conducted simultaneously from September 86 
2008 to August 2011 targeting girls aged 13-17. Overall uptake of three doses in this catch-up 87 
cohort was lower at 65% and varied by whether the individual was still at school at the time 88 
of vaccination and age.[3] The bivalent vaccine was used for the programme from 2008 to 89 
2012; at which time it was changed to the quadrivalent vaccine. To assess the impact of the 90 
bivalent HPV vaccine on virological, cytological and histological outcomes, a national HPV 91 
surveillance system was created in tandem with the vaccination programme and all data 92 
collected to date are from girls who received the bivalent vaccine. Utilising data from the 93 
surveillance system we have shown a significant reduction in prevalence of HPV 16 and 18 94 
and evidence of cross protection for HPV types 31, 33 and 45 associated with the bivalent 95 
HPV vaccine in 20 year old women attending for their first cervical screen.[4] In terms of 96 
disease outcomes, the bivalent vaccine has also been associated with a 55% reduction in high 97 
grade cervical intraepithelial neoplasia (CIN3) in women vaccinated as part of the catch-up 98 
programme [5] consistent with evidence from meta-analysis of data from nine countries.[6, 7]  99 
Furthermore in addition to the observed impacts on vaccinated women, early evidence of 100 
herd protection for HR-HPV infection in unvaccinated women has emerged in Scotland 101 
which is consistent with data from Australia.[8, 9]  102 
Deprivation, as measured by the Scottish Index of Multiple Deprivation (SIMD), is 103 
associated with increased cervical cancer incidence and mortality - both more than two-fold 104 
higher in women residing in the most deprived areas compared to the least deprived areas in 105 
Scotland.[10] This disparity can also be observed at the global level with low-income 106 
countries having significantly higher rates of cervical cancer, four fold in some cases, when 107 
compared to high income countries.[11] These differences are likely to be multifactorial and 108 
include lower level of engagement with cervical screening, earlier age of sexual debut and 109 
increased likelihood of smoking in those from more deprived backgrounds. [12-15]  110 
Although uptake of HPV vaccine in Scotland is generally high across all SIMD quintiles 111 
there is a lower likelihood of receiving all doses in the most deprived. In the first three years 112 
of the Scottish HPV immunisation programme, uptake of the first dose in the routine schools 113 
based cohort was high across all deprivation categories (~90%) but decreased linearly with 114 
increasing deprivation for doses two and three.[3] A similar pattern was seen in the catch-up 115 
programme where three dose uptake was 84.3-89.9% in those at school compared to ~30% in 116 
those who had left.[3] As school leavers are more likely to be from more deprived 117 
backgrounds, the substantially lower uptake in the out of school catch-up cohort coupled with 118 
the higher rates of cervical cancer in this group has the potential to widen the inequality gap 119 
between the least and most deprived women in Scotland with regards to incidence of cervical 120 
disease.  121 
The objective of the present work was to determine the effect that the introduction of the 122 
bivalent HPV vaccine has had on the inequality gap by measuring the incidence rates of 123 
CIN1, CIN2 and CIN3 at first cervical screen stratified by deprivation category and 124 
vaccination status.  125 
  126 
METHODS  127 
OVERVIEW OF THE SCOTTISH HPV SURVEILLANCE SYSTEM  128 
The methodology and processes involved in HPV surveillance in Scotland has been described 129 
previously.[4, 5] In summary, HPV surveillance is longitudinal and is facilitated by the use of 130 
an unique patient identifier, the community health index (CHI) number which allows for 131 
linkage of vaccination status to viral and disease outcomes.  132 
Since 2008, the Information Services Division (ISD) of the Scottish National Health Service 133 
(NHS) provides Health Protection Scotland (HPS) with an annual update of the HPV 134 
surveillance cohort which contains anonymised data on all medically registered women born 135 
in Scotland between 1988 and, as of the end of 2015, 1994. These data are linked by ISD to 136 
HPV vaccination data from the Scottish Immunisation Call-Recall System (SIRS), the Child 137 
Health Schools Programme-System (CHSP-S) and the Scottish Index of Multiple Deprivation 138 
(SIMD) using the CHI number. The linked records are anonymised and assigned a unique 139 
reference number before HPS review.   140 
SIMD is an index of multiple deprivation in Scotland which takes into account employment, 141 
income, health, crime, housing, education and access to services in small areas termed 142 
datazones. This deprivation index is then mapped to individuals based on their postcode of 143 
residence and quintiles of the score calculated overall. Individuals scoring SIMD 1 represent 144 
those that reside in the 20% most deprived areas while SIMD 5 represents those that reside in 145 
the 20% least deprived areas.    146 
LINKAGE 147 
The national Scottish Cervical Screening Call and Recall System (SCCRS) is an information 148 
technology system used by the Scottish cervical screening programme. It contains 149 
longitudinal cervical screening records for all eligible women in Scotland and incorporates 150 
pathology, virology, recall and management information for all eligible women in Scotland. 151 
ISD send records of all 20 and 21 year olds attending for their first cervical screen to HPS on 152 
an annual basis covering the birth cohorts from 1988 to 1994. If a woman is referred to 153 
colposcopy, her results are captured in the National Colposcopy Clinical Information and 154 
Audit System (NCCIAS). HPS receives NCCIAS data for those in the monitored HPV 155 
surveillance cohorts on a quarterly basis and up to 12 to 18 months of follow is available for 156 
each woman.  157 
ANALYSIS OF CIN IN WOMEN ATTENDING FOR FIRST SMEAR ACCORDING TO 158 
DEPRIVATION AND VACCNATION STATUS  159 
Incident abnormal histological episodes (CIN 1, CIN 2 and CIN 3) occurring within the first 160 
year following the first cervical screen in women aged 20 or 21 years born between 1988 to 161 
1994 were considered for each woman.  162 
The incidence rates of CIN 1, CIN 2 and CIN 3 per 1000 person-years were calculated by 163 
comparing the numbers of each diagnosis to the person-time contribution of each screened 164 
women. Incidence rates and associated 95% confidence intervals were stratified by SIMD 165 
quintile and the number of doses received. The relative risk of each grade of CIN in 166 
vaccinated women compared to unvaccinated women was calculated using Poisson 167 
regression, adjusting for birth cohort to model potential sociological differences between 168 
cohorts with person-time contribution used as an offset. As the relative risks of each grade of 169 
CIN were calculated with reference to those with no disease, the person-time contribution of 170 
women with a different disease outcome to the one being assessed was not included in the 171 
calculation of the rates. Adjusted relative risks were calculated using a similar approach but 172 
with the inclusion of an interaction term between SIMD quintile and the number of doses 173 
received to consider potential differences on the impact of the vaccination on disease by 174 
deprivation quintile.  All statistical analyses were performed in R version 3.2.0.  175 
Sensitivity analyses were performed for each grade of CIN; one model including only 176 
unvaccinated women, one including only those born from 1988 to August 1990 who would 177 
be unvaccinated as they were ineligible for vaccine and one including only those women born 178 
from 1991 to 1994 who were mostly vaccinated. These analyses were undertaken to remove 179 
potential sociological and temporal differences which may exist between those women who 180 
are vaccinated and unvaccinated which may confound vaccine effect.  181 
  182 
RESULTS 183 
Table 1 presents the characteristics of the women included in the study. Almost all women 184 
born in 1988 and 1989 were unvaccinated as they were not eligible to receive vaccine and 185 
therefore represent a baseline of CIN incidence in women attending for first screen in 186 
Scotland. As expected, the proportion of women receiving three doses of HPV vaccine 187 
increased with each new birth cohort from 1988 (0.03%) to 1994 (80.3%). Additionally, the 188 
numbers of each grade of CIN have decreased from 1988 to 1994. The proportion of 189 
unvaccinated women was higher in the most deprived quintile (58.7%) compared to the least 190 
deprived quintile (53.4%) with vaccine uptake increasing with increased affluence. The 191 
proportion of partially vaccinated women is also higher in the high deprivation categories. 192 
Figure 1 shows the proportion of screened women who are fully vaccinated increases with 193 
decreasing deprivation for each birth cohort. The number of women with CIN1, CIN 2 and 194 
CIN 3 generally decreases with decreasing deprivation.  195 
Table 1: Overview of characteristics of women included in study 196 
Birth year Screened Unvaccinated 1 dose 2 doses 3 doses CIN1 CIN2 CIN3 
1988 21830 99.95% 0.01% 0.01% 0.03% 274 276 248 
1989 20223 99.64% 0.12% 0.08% 0.15% 229 253 183 
1990 20542 81.45% 1.46% 2.69% 14.40% 216 224 201 
1991 20284 30.64% 3.02% 6.72% 59.61% 169 161 141 
1992 19807 20.37% 2.49% 5.02% 72.11% 148 113 90 
1993 19560 22.98% 2.82% 5.10% 69.10% 163 130 74 
1994 15461* 14.50% 1.74% 3.46% 80.30% 97 65 40 
SIMD quintile         
SIMD 1: Most 
deprived 30285 58.70% 2.54% 4.50% 34.26% 335 386 291 
SIMD 2 28859 56.09% 1.86% 3.60% 38.45% 280 295 262 
SIMD 3 26503 53.06% 1.49% 3.13% 42.31% 239 199 180 
SIMD 4 24557 52.86% 1.18% 2.72% 43.24% 207 191 137 
SIMD 5: Least 
deprived 27503 53.37% 0.96% 2.05% 43.62% 235 151 107 
TOTAL 137707 54.96% 1.64% 3.24% 40.16% 1296 1222 977 
*The numbers of screened women is lower in 1994 as these women had less follow-up time at data extraction 197 
Figure 2 (rates available in supplementary table S1) presents the incidence rates of CIN 1, 198 
CIN 2 and CIN 3 per 1000 person-years. Across all SIMD quintiles, the rate of cervical 199 
lesions is lower in fully vaccinated women compared to unvaccinated women. The difference 200 
in incidence rate between unvaccinated and fully vaccinated women is greater in those 201 
women diagnosed with more severe disease (CIN 2 and CIN 3) (Figure 2B and 2C). The 202 
decrease in incidence is more profound in the most deprived; for CIN 3 the rate in the 203 
unvaccinated and most deprived individuals (SIMD 1) is 14.5 per 1000 person-years (95% CI 204 
12.7-16.4) compared to 3.3 per 1000 person-years (95% CI 2.3-4.7) (p<0.001) in those 205 
vaccinated (Figure 2C). The corresponding results in the most affluent group (SIMD 5) is a 206 
shift from 5.1 per 1000 person-years (95% CI 4-6.5) (p<0.001) in the unvaccinated to 2.5 per 207 
1000 person-years (95% CI 1.7-3.6) (p=0.037) in the vaccinated. The pattern of impact is 208 
similar for CIN 2 (Figure 2B).  209 
For CIN 1, there was no significant evidence of a differential vaccine impact on incidence 210 
between SIMD quintile (Figure 2A, test of interaction SIMD and vaccine status, p-211 
value=0.275) therefore only a main effects model was considered (Table 2).  Calculation of 212 
adjusted relative risks (RR) showed a significant effect of 3 doses of vaccine associated with 213 
a reduction of CIN 1 burden (RR=0.83, 95% CI 0.69-0.98) (p=0.028). After adjustment for 214 
vaccine status and cohort year, the effect of deprivation remains, with those in the least 215 
deprived cohort less likely to have CIN 1 (SIMD 5 RR=0.78, 95% CI 0.66-0.92) (p=0.003). 216 
Sensitivity analyses did not significantly alter the relative risk estimates (Supplementary 217 
tables S2-S4).  218 
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Table 2:  Rates (per 1000 person year) and adjusted RR of CIN 1 by birth cohort, SIMD 232 
quintile and number of doses of vaccine received 233 
  Person-
years 
Number 
of CIN 1 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR (95% 
CI) 
p-value 
Number 
of doses 
0 72601 835 11.5 (10.7-12.3) 1 - 
 1 2152 16 7.4 (4.2-12.1) 0.752 (0.453-1.248) 0.271 
 2 4281 43 10.0 (7.3-13.5) 1.031 (0.744-1.428) 0.855 
 3 53325 402 7.5 (6.8-8.3) 0.825 (0.695-0.979) 0.028 
Birth 
cohort 
1988 20917 274 13.1 (11.6-14.7) 1 - 
 1989 19465 229 11.8 (10.3-13.4) 0.901 (0.756-1.073) 0.242 
 1990 19825 216 10.9 (9.5-12.4) 0.859 (0.717-1.029) 0.098 
 1991 19768 169 8.6 (7.3-9.9) 0.736 (0.590-0.917) 0.006 
 1992 19436 148 7.6 (6.4-8.9) 0.671 (0.529-0.851) 0.001 
 1993 18921 163 8.6 (7.3-10.0) 0.756 (0.601- 0.951) 0.017 
 1994 14028 97 6.9 (5.6-8.4) 0.622 (0.475-0.815) 0.001 
SIMD 
quintile 
SIMD 1: 
Most 
deprived 
28842 335 11.6 (10.4-12.9) 1 - 
 
SIMD 2 27669 280 10.1 (9.0-11.4) 0.878 (0.750-1.030) 0.110 
 SIMD 3 25527 239 9.4 (8.2-10.6) 0.822 (0.696-0.971) 0.021 
 SIMD 4 23706 207 8.7 (7.6-10.0) 0.765 (0.643-0.910) 0.002 
 
SIMD 5: 
Least 
deprived 
26614 235 8.8 (7.7-10.0) 0.777 (0.657-0.918) 0.00307 
 234 
Considering CIN 2 and CIN 3, there is evidence for a differential impact of vaccination 235 
across the deprivation quintiles (test of interaction SIMD and vaccine status for CIN 2 and 236 
CIN 3 both p-value <0.001).  Compared to the most deprived and unvaccinated individuals, 237 
the least deprived and unvaccinated women have reduced risk of CIN 2 (RR=0.47, 95% CI 238 
0.38-0.59) (p<0.001) (Table 3, Table 4). In those vaccinated and most deprived, there is a 239 
reduced risk of CIN 2 (RR=0.45 95% CI 0.33-0.6) (p<0.001) compared to most deprived and 240 
unvaccinated while those women who were vaccinated and least deprived had a similar 241 
reduction in disease (RR=0.38 95% CI 0.25-0.58) (p<0.001) compared to unvaccinated 242 
women in SIMD 5.  For CIN 2, the significance of the interaction between SIMD and vaccine 243 
impact is likely driven by the low incidence in the unvaccinated women from the SIMD 3 244 
group (Figure 2B), which then affects the vaccine impact in this group (RR=0.71; 95% CI 0.51-0.99) (p=0.041).  245 
Table 3: Rates (per 1000 person year) and adjusted RR* of CIN 2 and 3 by birth cohort 246 
Birth 
cohort 
Number 
of CIN 2 
Person-
years 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR 
(95% CI) 
p-value  
Number 
of CIN 3 
Person-
years 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR (95% 
CI) 
p-value 
1988 276 20904 13.2 (11.7-14.9) 1  -  248 20891 11.9 (10.4-13.4)  1 - 
1989 253 19474 13 (11.4-14.7) 0.99 (0.84-1.18) 0.924  183 19438 9.4 (8.1-10.9) 0.8 (0.661-0.968) 0.022 
1990 224 19818 11.3 (9.9-12.9) 0.93 (0.78-1.11) 0.435  201 19800 10.2 (8.8-11.7) 0.946 (0.785-1.141) 0.565 
1991 161 19755 8.2 (6.9-9.5) 0.89 (0.72-1.11) 0.294  141 19748 7.1 (6-8.4) 0.941 (0.748-1.185) 0.606 
1992 113 19414 5.8 (4.8-7) 0.7 (0.55-0.9) 0.005  90 19394 4.6 (3.7-5.7) 0.692 (0.527-0.908) 0.008 
1993 130 18884 6.9 (5.8-8.2) 0.81 (0.64-1.03) 0.081  74 18857 3.9 (3.1-4.9) 0.567 (0.426-0.754) <0.001 
1994 65 14007 4.6 (3.6-5.9)  0.61 (0.45-0.82) 0.001  40 13993 2.9 (2-3.9)  0.476 (0.331-0.685) <0.001 
*The relative risk (RR) for each birth cohort is adjusted for the interaction of Scottish Index of Multiple Deprivation (SIMD) quintile and number of doses 247 
of vaccine received. 248 
For CIN 3, the differential impact of the vaccine by deprivation quintile is clear (Table 3, Table 4).  Compared to the most deprived and 249 
unvaccinated group, those vaccinated in the same deprivation quintile have a significantly reduced risk (RR=0.29 95% CI 0.2 -0.43) (p<0.001).  250 
The impact for those vaccinated in the least deprived group (SIMD 5) is less evident (RR=0.62 95% CI 0.4-0.97) (p=0.037) when compared to 251 
unvaccinated, least deprived group illustrated by Figure 2C and reflective of the lower incidence rate in the unvaccinated individuals in SIMD 5. 252 
Sensitivity analyses of the models for CIN 2 and CIN 3 showed small differences to the relative risk estimates compared to the full model but 253 
did not change the overall conclusions  (Supplementary tables S2-S4).  254 
 255 
 256 
Table 4:  Rates (per 1000 person year) and adjusted RR* of CIN 2 and 3 by the combination of Scottish Index of Multiple Deprivation 257 
(SIMD) quintile and number of doses of vaccine received. 258 
SIMD 
quintile 
Number 
of doses 
Number 
of CIN 2 
Person-
years 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR 
(95% CI) 
p-value  
Number 
of CIN 3 
Person-
years 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR 
(95% CI) 
p-value 
SIMD 1: 
Most 
deprived 0 296 16830 17.6 (15.6-19.7) 1 - 
 
243 16816 14.5 (12.7-16.4) 1 - 
SIMD 2 
0 215 15500 13.9 (12.1-15.9) 0.79 (0.66-0.94) 0.008 
 
204 15490 13.2 (11.4-15.1) 
0.909 (0.755-
1.095) 0.316 
SIMD 3 0 128 13528 9.5 (7.9-11.3) 0.54 (0.44-0.66) <0.001  127 13523 9.4 (7.8-11.2) 0.65 (0.524-0.805) <0.001 
SIMD 4 
0 139 12516 11.1 (9.3-13.1) 0.63 (0.51-0.77) <0.001 
 
104 12495 8.3 (6.8-10.1) 
0.571 (0.454-
0.719) <0.001 
SIMD 5: 
Least 
deprived 0 118 14207 8.3 (6.9-9.9) 0.47 (0.38-0.59) <0.001 
 
73 14188 5.1 (4-6.5) 
0.357 (0.275-
0.463) <0.001 
 
            
SIMD 1: 
Most 
deprived 1 15 727 20.6 (11.5-34) 1.39 (0.82-2.36) 0.225 
 
5 725 6.9 (2.2-16.1) 0.58 (0.237-1.416) 0.232 
SIMD 2 
1 1 517 1.9 (0.1-10.8) 0.16 (0.02-1.16) 0.070 
 
9 517 17.4 (8-33) 
1.551 (0.789-
3.051) 0.203 
SIMD 3 1 7 377 18.6 (7.5-38.2) 2.26 (1.05-4.87) 0.038  6 375 16 (5.9-34.8) 1.969 (0.862-4.5) 0.108 
SIMD 4 
1 4 279 14.3 (3.9-36.7) 1.48 (0.54-4.01) 0.444 
 
1 278 3.6 (0.1-20) 
0.493 (0.069-
3.544) 0.482 
SIMD 5: 
Least 
deprived 1 0 253 0 0 - 
 
1 253 4 (0.1-22) 
0.884 (0.123-
6.376) 0.903 
SIMD 1: 
Most 
deprived 2 11 1296 8.5 (4.2-15.2) 0.57 (0.31-1.05) 0.072 
 
10 1295 7.7 (3.7-14.2) 0.641 (0.337-1.22) 0.175 
SIMD 2 
2 20 987 20.3 (12.4-31.3) 1.71 (1.07-2.74) 0.025 
 
7 984 7.1 (2.9-14.7) 
0.633 (0.295-
1.356) 0.239 
SIMD 3 2 5 801 6.2 (2.1-14.6) 0.76 (0.31-1.87) 0.552  9 803 11.2 (5.1-21.3) 1.38 (0.695-2.739) 0.357 
SIMD 4 
2 5 648 7.7 (2.5-18) 0.8 (0.33-1.97) 0.631 
 
2 649 3.1 (0.4-11.1) 
0.423 (0.104-
1.722) 0.230 
SIMD 5: 
Least 
deprived 2 3 543 5.5 (1.1-16.2) 0.76 (0.24-2.4) 0.639 
 
4 543 7.4 (2-18.9) 
1.605 (0.584-
4.417) 0.359 
SIMD 1: 
Most 
deprived 3 64 9975 6.4 (4.9-8.2) 0.45 (0.33-0.6) <0.001 
 
33 9960 3.3 (2.3-4.7) 0.292 (0.199-0.43) <0.001 
SIMD 2 
3 59 10658 5.5 (4.2-7.1) 0.49 (0.36-0.67) <0.001 
 
42 10640 3.9 (2.8-5.3) 
0.384 (0.268-
0.549) <0.001 
SIMD 3 
3 59 10802 5.5 (4.2-7) 0.71 (0.51-0.99) 0.041 
 
38 10789 3.5 (2.5-4.8) 
0.477 (0.325-
0.702) <0.001 
SIMD 4 3 43 10240 4.2  (3-5.7) 0.47 (0.32-0.67) <0.001  30 10231 2.9 (2-4.2) 0.45 (0.294-0.691) <0.001 
SIMD 5: 
Least 
deprived 3 30 11572 2.6 (1.7-3.7) 0.38 (0.25-0.58) <0.001 
 
29 11566 2.5 (1.7-3.6) 0.62 (0.395-0.972)  0.037 
*The relative risk (RR) for each combination of number of doses and SIMD is adjusted for birth cohort. 259 
 260 
 261 
DISCUSSION 262 
The uptake of cervical screening in Scotland in women aged 20-60 has gradually decreased 263 
over the last 10 years and dropped below 70% for the time since 2007.[16] Therefore, HPV 264 
vaccination is increasingly important in the primary prevention of cervical cancer. We have 265 
shown that the bivalent vaccine is significantly associated with reductions of CIN 1, CIN 2 266 
and CIN 3, with vaccine effectiveness against CIN 2 and CIN 3 greater in those women from 267 
the most deprived categories. These findings are welcome due to the higher rates of cervical 268 
cancer and poorer outcomes in women in SIMD 1. Our findings also allay the concern that 269 
HPV immunisation would further widen the inequality gap between the least and most 270 
deprived women with regards to rates of cervical disease.[2] Paired with evidence of herd 271 
immunity against HPV 16 and 18 in the unvaccinated population from those born 1993 272 
onwards,[8] those most at risk are benefitting from protection against cervical disease. 273 
Nevertheless, there remains a cohort of unvaccinated women in SIMD 1 in which there are 274 
higher rates of cervical disease compared to the unvaccinated least deprived women, albeit a 275 
small number, and therefore the benefits of regular screening must be reiterated. 276 
We have previously shown that bivalent HPV vaccine is associated with reductions in low 277 
and high grade cervical abnormalities.[5] Evidence of reductions in cervical abnormalities is 278 
also being demonstrated elsewhere. An Australian study presented quadrivalent vaccine 279 
effectiveness of 46% against high grade cervical abnormalities and a study in the United 280 
States reported vaccine effectiveness estimates against HPV 16/18- attributable CIN 2+ of 281 
between 21% to 72%, depending on time between vaccination and diagnosis of CIN 2+.[17, 282 
18] We observed no significant reduction in CIN 1, 2 or 3 in women who were partially 283 
vaccinated despite a reduction in HPV prevalence in those women in a study of Scottish data. 284 
This may be confounded by differences in sociological factors which may exist between 285 
those who received only a partial number of doses compared to those who receive the full 286 
regimen and the fact only a small number women are partially vaccinated in Scotland.[19] As 287 
further data accrue, we aim to investigate the impact of partial vaccination on disease 288 
outcomes. 289 
Inequalities in cervical screening uptake in the UK and in other developed countries are well 290 
documented with women from deprived backgrounds less likely to attend.[20-24] Several 291 
factors have been identified which contribute to non-attendance of women at cervical 292 
screening including perception of risk of developing cervical cancer being low, the potential 293 
for embarrassment and pain, a lack of knowledge about the purposes of cervical screening 294 
and anxiety about the results.[23, 24] These factors may disproportionately affect more 295 
deprived women due to lower educational attainment which has been shown to be associated 296 
with non-attendance at cervical screening.[25] Notably, a recent analysis of Scottish data 297 
showed that screening uptake, in vaccine eligible women, is higher in the most deprived 298 
women.[26] This contrast with previous research may be related to differences in the usage of 299 
health services or increased movement of the least deprived women.[26] It is welcoming that 300 
the Scottish data so far indicate that inequitable uptake of vaccine in the catch-up cohort and 301 
cervical screening has not led to a widening of the difference in rates of CIN between the 302 
most and least deprived.  303 
 A major strength of our study is that we utilised data from large national databases which 304 
were linked to immunisation status via a unique patient identifier, allowing the impact of the 305 
HPV vaccine to be assessed directly. There are, however, some limitations associated with 306 
the study. The lack of sexual history data and the fact that all women included in the study 307 
received vaccine as part of the catch-up campaign may lead to lower estimates of vaccine 308 
effect than is likely to be observed in those routinely vaccinated at age 12. Another limitation 309 
is that the majority of unvaccinated women are from the 1988 and 1989 cohort; comparisons 310 
of  rates between unvaccinated and vaccinated women is partly a temporal comparison, 311 
therefore, the differences may be confounded by changes in behaviours and sexual practices 312 
over time. This is partly adjusted for in the Poisson regression analysis by including birth 313 
cohort but cannot fully account for sexual history and practices. However, results of the 314 
National Survey of Sexual Attitudes and Lifestyles (NATSAL) study have actually shown an 315 
increase in the number of sexual partners in women over time, which is known to increase the 316 
risk of HR-HPV infection. Thus the decrease is unlikely to be due to changes in sexual 317 
practices alone.[27] Results from sensitivity analyses (Supplementary tables S2-S4) show 318 
that temporal changes and/or sociological differences are unlikely to have had a substantial 319 
effect on our conclusions.   320 
While SIMD is an effective method of estimating deprivation it does have limitations. A 321 
SIMD score is assigned based on postcode of residence and therefore shows an individual is 322 
from a deprived area but LWPD\QRWDFFXUDWHO\UHSUHVHQWDQLQGLYLGXDO¶VWUXHGHSULYDWLRQ323 
status.[28] Also, as seven different aspects of deprivation are considered, an individual may 324 
be categorised as being deprived based on aspects which are not as relevant to the likelihood 325 
of receiving HPV immunisation and attending for cervical screening. For example, an 326 
individual may be from an area which scores low on crime and housing conditions but scores 327 
more highly on geographical access and education which may be more influential on 328 
LQGLYLGXDO¶VKHDOWKVHHNLQJEHKDYLRXU  329 
Our results are derived from those who have attended for their first screen at age 20-21 and 330 
are thus not wholly representative of the Scottish population where around half of all cancers 331 
are detected in those who have never attended for screening. Excluding women who attend 332 
their first cervical screen later in life will also underestimate the true burden of cervical 333 
disease and may bias our sample towards less deprived, vaccinated women. Studies in 334 
Scotland and the US have shown that screening uptake is higher in vaccinated women and 335 
therefore vaccine effect may be overestimated in our study.[26, 29] It should be noted that 336 
deprived women who engage with cervical screening may be socially and culturally different 337 
to those that do not, potentially confounding the vaccine effect in the most deprived but this 338 
is tempered by the inclusion of the 1988 and 1989 birth cohorts who were ineligible to 339 
receive vaccine. 340 
The bivalent HPV vaccine in Scotland is associated with a reduction in the inequality in 341 
cervical disease between deprivation groups by decreasing the incidence of high grade 342 
cervical lesions in the most deprived women who attend screening to rates comparable to a 343 
level in the least deprived category. Our results are encouraging for other countries, including 344 
those with inequitable uptake.  345 
 346 
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  469 
Figure 1: Proportion of women who attended for first screen aged 20-21 who are fully vaccinated (3 470 
doses) by birth cohort and deprivation (SIMD) quintile (based on location of residence SIMD 1: most 471 
deprived 20%,  SIMD 5: least deprived 20%) 472 
 473 
  474 
Figure 2: Incidence rate per 1000 person-years (p1000py) of  (A) CIN 1,(B)  CIN 2 and (C) CIN 3 by deprivation (SIMD) quintile (based on location of 475 
residence SIMD 1: most deprived 20%,  SIMD 5: least deprived 20%) in unvaccinated and fully vaccinated (3 doses) women 476 
477 
Supplementary tables  478 
Table S1: Rates, unadjusted and adjusted relative risks of CIN1, CIN2 and CIN3 in 1 year following first smear in 20-21 year old women born 479 
between 1988 to 1994 by vaccination status and deprivation  480 
CIN1  Rate per 1000py (95% CI) 
   Unvaccinated Fully vaccinated 
 SIMD 1 14 (12.2-15.9) 7.71 (6.08-9.63) 
 SIMD 2 11.03 (9.44-12.82) 8.71 (7.03-10.67) 
 SIMD 3 11.44 (9.71-13.39) 7.12 (5.62-8.9) 
 SIMD 4 10.85 (9.11-12.83) 6.43 (4.97-8.18) 
 SIMD 5 9.7 (8.15-11.46) 7.67 (6.16-9.43)  
CIN 2    
 SIMD 1 17.58 (15.63-19.7) 6.41 (4.94-8.19) 
 SIMD 2 13.86 (12.07-15.84) 5.53 (4.21-7.14) 
 SIMD 3 9.46 (7.89-11.24) 5.46 (4.16-7.04) 
 SIMD 4 11.1 (9.33-13.1) 4.2 (3.04-5.65) 
 SIMD 5 8.3 (6.87-9.94) 2.59 (1.75-3.7)  
 CIN 3 
  
 SIMD 1 14.44 (12.68-16.37) 3.31 (2.28-4.65) 
 SIMD 2 13.16 (11.42-15.1) 3.94 (2.84-5.33) 
 SIMD 3 9.38 (7.82-11.17) 3.52 (2.49-4.83) 
 SIMD 4 8.32 (6.8-10.1) 2.93 (1.98-4.18) 
 SIMD 5 5.14 (4.03-6.46) 2.51 (1.68-3.6) 
 481 
 482 
 483 
 484 
Table S2a: Adjusted RR of CIN 1, CIN 2 and CIN 3 by birth cohort and SIMD quintile in unvaccinated women  485 
 CIN 1 CIN 2 CIN 3 
SIMD quintile  RR (95% CI) p-value RR (95% CI) p-value RR (95% CI) p-value 
1 1  1  1  
2 0.79 (0.65-0.96) 0.018 0.79 (0.66-0.94) 0.008 0.91 (0.75-1.1) 0.316 
3 0.82 (0.67-1) 0.052 0.54 (0.44-0.66) <0.001 0.65 (0.52-0.81) <0.001 
4 0.77 (0.62-0.95) 0.016 0.63 (0.51-0.77) <0.001 0.57 (0.45-0.72) <0.001 
5 0.7 (0.56-0.86) <0.001 0.47 (0.38-0.59) <0.001 0.36 (0.27-0.46) <0.001 
Birth cohort        
1988 1  1  1  
1989 0.9 (0.75-1.07) 0.235 0.99 (0.83-1.17) 0.905 0.8 (0.66-0.97) 0.023 
1990 0.84 (0.70-1.01) 0.07 0.87 (0.72-1.05) 0.14 0.94 (0.77-1.14) 0.5 
1991 0.86 (0.66-1.12) 0.261 0.94 (0.73-1.22) 0.652 0.9 (0.68-1.18) 0.446 
1992 0.68 (0.48-0.97) 0.031 0.84 (0.61-1.16) 0.29 0.81 (0.58-1.14) 0.234 
1993 0.64 (0.45-0.9) 0.011 0.85 (0.63-1.15) 0.299 0.58 (0.4-0.85) 0.005 
1994 0.66 (0.4-1.07) 0.094 0.59 (0.35-0.99) 0.046 0.53 (0.3-0.94) 0.031 
 486 
 487 
 488 
 489 
 490 
 491 
 492 
 493 
 494 
Table S3a: Adjusted RR of CIN 1, CIN 2 and CIN 3 by birth cohort and SIMD quintile in women born 1988-1990 495 
 CIN 1 CIN 2 CIN 3 
SIMD quintile  RR (95% CI) p-value RR (95% CI) p-value RR (95% CI) p-value 
1 1  1  1  
2 0.68 (0.52-0.88) 0.003 0.78 (0.62-0.99) 0.039 1 (0.78-1.29) 0.972 
3 0.83 (0.64-1.07) 0.142 0.55 (0.42-0.72) <0.001 0.7 (0.55-0.96) 0.024 
4 0.77 (0.59-1) 0.05 0.65 (0.5-0.84) 0.001 0.66 (0.49-0.88) <0.001 
5 0.73 (0.56-0.94) 0.016 0.61 (0.47-0.79) <0.001 0.42 (0.3-0.59) <0.001 
Birth cohort        
1988 1  1  1  
1989 0.9 (0.75-1.07) 0.237 0.99 (0.83-1.17) 0.902 0.8 (0.66-0.97) 0.021 
1990 0.91 (0.58-1.43) 0.685 0.78 (0.48-1.28) 0.330 0.71 (0.42-1.22) 0.218 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
Table S4a: Adjusted RR of CIN 1 by birth cohort and SIMD quintile in women born 1991-1994 507 
CIN 1 
Dose RR (95% CI) p-value 
0 1  
1 0.67 (0.37-1.2) 0.175 
2 1.05 (0.74-1.5) 0.789 
3 0.79 (0.65-0.96) 0.016 
SIMD   
1 1  
2 1.04 (0.82-1.32) 0.740 
3 0.83 (0.64-1.07) 0.159 
4 0.75 (0.57-0.99) 0.044 
5 0.9 (0.7-1.15) 0.403 
Birth cohort    
1991 1  
1992 0.92 (0.73-1.14) 0.44 
1993 1.03 (0.83-1.28) 0.777 
1994 0.85 (0.66-1.1) 0.213 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
Table S4b: Adjusted RR of CIN 2 and CIN 3 by birth cohort and the combination of SIMD quintile and number of doses of vaccine received in women born 516 
1991-1994 517 
 CIN 2 CIN 3 
Birth cohort 
Adjusted RR 
(95% CI) p-value 
Adjusted RR 
(95% CI) p-value 
1991 1  1  
1992 0.8 (0.63-1.02) 0.067 0.74 (0.57-0.97) 0.029 
1993 0.92 (0.73-1.16) 0.478 0.61 (0.46-0.81) <0.001 
1994 0.71 (0.53-0.95) 0.022 0.52 (0.37-0.75) <0.001 
SIMD quintile 
Number of 
doses   
  
1 0 1 - 1 - 
2 0 0.62 (0.43-0.9) 0.012 0.76 (0.51-1.14) 0.192 
3 0 0.43 (0.28-0.68) <0.001 0.49 (0.3-0.8) 0.005 
4 0 0.51 (0.32-0.81) 0.004 0.51 (0.3-0.86) 0.012 
5 0 0.21 (0.12-0.38) <0.001 0.15 (0.07-0.33) <0.001 
      
1 1 1.02 (0.57-1.83) 0.949 0.54 (0.22-1.33) 0.180 
2 1 0.2 (0.03-1.42) 0.106 1.9 (0.92-3.93) 0.082 
3 1 1.84 (0.7-4.8) 0.214 1.76 (0.6-5.12) 0.301 
4 1 1.36 (0.41-4.52) 0.614 0 0.992 
5 1 0 0.992 2.39 (0.29-19.43) 0.415 
1 2 0.31 (0.14-0.66) 0.003 0.59 (0.3-1.15) 0.122 
2 2 1.88 (1.09-3.23) 0.023 0.75 (0.33-1.67) 0.476 
3 2 0.86 (0.33-2.24) 0.752 1.43 (0.61-3.35) 0.416 
4 2 0.74 (0.26-2.12) 0.569 0.49 (0.11-2.09) 0.332 
5 2 0.55 (0.07-4.22) 0.566 4.01 (1.17-13.69) 0.027 
1 3 0.32 (0.23-0.45) <0.001 0.23 (0.15-0.36) <0.001 
2 3 0.45 (0.3-0.68) <0.001 0.38 (0.25-0.6) <0.001 
3 3 0.68 (0.42-1.09) 0.107 0.49 (0.28-0.85) 0.011 
4 3 0.38 (0.23-0.64) <0.001 0.38 (0.21-0.69) 0.002 
5 3 0.62 (0.32-1.21) 0.161 1.06 (0.46-2.46) 0.890 
 518 
